U.S. markets open in 57 minutes
  • S&P Futures

    4,079.25
    -10.75 (-0.26%)
     
  • Dow Futures

    34,019.00
    -137.00 (-0.40%)
     
  • Nasdaq Futures

    12,140.00
    -12.00 (-0.10%)
     
  • Russell 2000 Futures

    1,936.00
    -3.40 (-0.18%)
     
  • Crude Oil

    79.37
    +0.50 (+0.63%)
     
  • Gold

    1,947.10
    +1.80 (+0.09%)
     
  • Silver

    23.70
    -0.13 (-0.55%)
     
  • EUR/USD

    1.0908
    +0.0041 (+0.38%)
     
  • 10-Yr Bond

    3.5290
    0.0000 (0.00%)
     
  • Vix

    19.55
    -0.39 (-1.96%)
     
  • GBP/USD

    1.2343
    +0.0026 (+0.21%)
     
  • USD/JPY

    129.5310
    -0.5370 (-0.41%)
     
  • BTC-USD

    23,118.36
    +182.41 (+0.80%)
     
  • CMC Crypto 200

    523.80
    +5.00 (+0.96%)
     
  • FTSE 100

    7,789.26
    +17.56 (+0.23%)
     
  • Nikkei 225

    27,346.88
    +19.77 (+0.07%)
     

AC Immune Provides Update On Alzheimer's Disease Vaccine Candidate

  • AC Immune SA (NASDAQ: ACIU) and its partner Janssen Pharmaceuticals Inc have expanded the ongoing Phase 1b/2a trial evaluating anti-phosphorylated-Tau (pTau) vaccine candidate ACI-35.030 for the treatment of Alzheimer's disease (AD).

  • The trial expansion specifically includes vaccination of additional AD patients at the second-highest dose.

  • In parallel, the trial continues to evaluate patients in the highest dose cohort, for which the first interim results will be available by the end of this year.

  • Interim Phase 1b/2a trial results from the low and second-highest dose groups showed vaccination generated a potent antigen-specific antibody response against pTau in 100% of older patients with early AD with no clinically relevant safety concerns observed to date.

  • In addition to ACI-35.030, AC Immune and Janssen Pharmaceuticals are evaluating an exploratory alternative pTau vaccine candidate, JACI-35.054, in the current Phase 1b/2a trial.

  • Price Action: ACIU shares are up 2.56% at $6.37 on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.